CN106701650A - Riemerella anatipestifer gene deletion low virulent strain and construction method and application thereof - Google Patents
Riemerella anatipestifer gene deletion low virulent strain and construction method and application thereof Download PDFInfo
- Publication number
- CN106701650A CN106701650A CN201710022087.6A CN201710022087A CN106701650A CN 106701650 A CN106701650 A CN 106701650A CN 201710022087 A CN201710022087 A CN 201710022087A CN 106701650 A CN106701650 A CN 106701650A
- Authority
- CN
- China
- Prior art keywords
- spec
- strain
- primer
- seq
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001478212 Riemerella anatipestifer Species 0.000 title claims abstract description 30
- 238000010276 construction Methods 0.000 title claims abstract description 13
- 238000012224 gene deletion Methods 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 89
- 229960005486 vaccine Drugs 0.000 claims abstract description 13
- 239000002773 nucleotide Substances 0.000 claims description 43
- 125000003729 nucleotide group Chemical group 0.000 claims description 43
- 230000003321 amplification Effects 0.000 claims description 38
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 38
- 241000894006 Bacteria Species 0.000 claims description 31
- 239000013612 plasmid Substances 0.000 claims description 26
- 108091008146 restriction endonucleases Proteins 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 20
- 241000272525 Anas platyrhynchos Species 0.000 claims description 18
- 230000029087 digestion Effects 0.000 claims description 18
- 238000001962 electrophoresis Methods 0.000 claims description 17
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 15
- 238000001976 enzyme digestion Methods 0.000 claims description 13
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 230000006798 recombination Effects 0.000 claims description 7
- 238000005215 recombination Methods 0.000 claims description 7
- 238000012408 PCR amplification Methods 0.000 claims description 6
- 238000004925 denaturation Methods 0.000 claims description 6
- 230000036425 denaturation Effects 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000013641 positive control Substances 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 108091036078 conserved sequence Proteins 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 238000005238 degreasing Methods 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 229930027917 kanamycin Natural products 0.000 claims description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 3
- 238000007790 scraping Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 229960002518 gentamicin Drugs 0.000 claims description 2
- 229960000268 spectinomycin Drugs 0.000 claims description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims description 2
- 229940031567 attenuated vaccine Drugs 0.000 claims 1
- 230000005611 electricity Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000009182 swimming Effects 0.000 claims 1
- 230000001018 virulence Effects 0.000 abstract description 2
- 108010070675 Glutathione transferase Proteins 0.000 abstract 1
- 102000005720 Glutathione transferase Human genes 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 10
- 239000002574 poison Substances 0.000 description 9
- 231100000614 poison Toxicity 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940031551 inactivated vaccine Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 231100000111 LD50 Toxicity 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 3
- 206010021703 Indifference Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MVEOHWRUBFWKJY-UHFFFAOYSA-N 7-hydroxynaphthalene-2-sulfonic acid Chemical group C1=CC(S(O)(=O)=O)=CC2=CC(O)=CC=C21 MVEOHWRUBFWKJY-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000003450 growing effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940032021 tetramune Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a riemerella anatipestifer gene deletion low virulent strain and a construction method and application thereof. The strain is riemerella anatipestifer CH-1deltaB739_1343, is preserved in the Chinese typical culture collection center and is assigned the accession number CCTCC NO: M2016438, 2352bp of B739_1343 genes of a heme transfer system is deleted, and the deleted gene sequence is as shown in SEQ ID No. 1. Animal experimental results indicate that the LD50 value of the deleted strain is larger than 10<10>CFU, the LD50 value of RA-CH-1 is about 10<8>CFU, the duckling virulence of the deleted strain is reduced by at least 100 times, the toxin attacking protection rate of the low virulent strain against 100*LD50 wild virulent strain RA-CH-1 is 83.33%, and the strain can serve as a candidate strain for RA gene deletion vaccines.
Description
Technical field
The invention belongs to biological technical field, specifically, it is related to one plant of riemerella anatipestifer gene delection low virulent strain
And its construction method and application.
Background technology
Riemerella anatipestifer disease is caused by riemerella anatipestifer (Riemerella anatipestifer, RA)
A kind of main acute or chronic contagious disease for infecting various birds such as duckling.The disease has a very wide distribution, it has also become tight
One of bacterial infectious disease of duck culturing industry is endangered again.At present, the major measure that China controls this sick is that vaccine prevention and medicine are controlled
Treat.Because riemerella anatipestifer is present without cross-protection between various serotype and each serology, so a kind of vaccine
Can only be worked for One serotype.And medicine is a large amount of using causing the drug resistance of RA constantly to strengthen, while also giving food
Cause potential safety hazard.So the new generation vaccine for developing prevention RA diseases is following developing direction.
Ferro element is nutrient necessary to most biology growings, including bacterium.However, host is by " battalion
Support immune " mechanism significantly limit iron using degree.Therefore pathogen must possess iron transfer mechanism could successfully infect
Host.Conversely, if pathogen iron ion were damaged using system, the reduced capability of infection host.Can using this principle
To produce riemerella anatipestifer low virulent strain and be used for immunoprophylaxis.
The content of the invention
In view of this, the present invention is directed to above-mentioned problem, there is provided one plant of riemerella anatipestifer gene delection low virulent strain
And its construction method and application.
In order to solve the above-mentioned technical problem, the invention discloses one plant of riemerella anatipestifer gene delection low virulent strain, should
Bacterial strain is riemerella anatipestifer CH-1 Δ B739_1343, is named as Riemerella anatipestifer CH-1 Δs
B739_1343, China typical culture collection center is preserved on 30th in August in 2016, and its preserving number is CCTCC NO:
M2016438, the bacterial strain has lacked the 2352bp of ferroheme movement system B739_1343 genes, and the gene order for being lacked is such as
Shown in SEQ ID NO.1.
The invention also discloses a kind of construction method of riemerella anatipestifer gene delection low virulent strain, including following step
Suddenly:
1) PCR amplifications RA-CH-1B739_1343 genes or so homology arm and Spec resistant genes;
2) the RA-CH-1B739_1343 genes that will have been expanded or so homology arm and Spec resistant genes carry out digestion and connect
Night is taken over, B739_1343-LSR fragments are built;
3) recombination suicide vector pEX18GM Δs B739_1343-LSR is built;
4) RA-CH-1B739_1343 gene-deleted strains are built, RA-CH-1B739_1343 gene-deleted strains are in pest of duck
Mo Shi bacillus genes lack low virulent strain.
Further, step 1) in PCR amplification RA-CH-1B739_1343 genes or so homology arm and Spec resistant genes
Specially:
1.1) two couples of primer B739_1343-L F/R and B739_ are designed according to B739_1343 genes or so homology arm
1343-R F/R, and in primer 5 '-end addition restriction enzyme digestion sites;By the use of RA-CH-1 genomes as template, point
It is primer amplification B739_1343 genes or so homology arm fragment not with B739_1343-L F/R and B739_1343-R F/R
B739_1343-L and B739_1343-R;PCR conditions are:98 DEG C of denaturation 30s, through 98 DEG C of 10s, 55 DEG C of 30s, 72 DEG C of 30s circulations
Amplification 30 times, 72 DEG C of extension 7min;
Wherein, B739_1343-L F/R include B739_1343-L F and B739_1343-L R, B739_1343-L F's
Nucleotide sequence is BamHI in primer 5 '-end addition restriction enzyme digestion sites as shown in SEQ ID NO.5;
The nucleotide sequence of B739_1343-L R adds digestion with restriction enzyme as shown in SEQ ID NO.6 at primer 5 '-end
Site is NheI;
B739_1343-R F/R include the nucleotides of B739_1343-R F and B739_1343-R R, B739_1343-R F
Sequence is EcoRI in primer 5 '-end addition restriction enzyme digestion sites as shown in SEQ ID NO.7;B739_1343-
The nucleotide sequence of R R is KpnI in primer 5 '-end addition restriction enzyme digestion sites as shown in SEQ ID NO.8;
1.2) the Spec resistance gene fragments design primer Spec F/R in plasmid pAM238, and at primer 5 '-end
Add NheI, EcoRI restriction enzyme site;By the use of plasmid pAM238 as template, Spec sequences are expanded by primer PCR of Spec F/R
Row;PCR conditions are:98 DEG C of denaturation 30s, through 98 DEG C of 10s, 55 DEG C of 30s, 72 DEG C of 50s cyclic amplifications 30 times, 72 DEG C of extension 7min;
Wherein, the nucleotide sequence of Spec F/R including Spec F and Spec R, Spec F is as shown in SEQ ID NO.9,
And add NheI restriction enzyme sites at primer 5 '-end;The nucleotide sequence of Spec R as shown in SEQ ID NO.10, and in primer
5 '-end adds EcoRI restriction enzyme sites.
Further, step 2) in structure B739_1343-LSR fragments be specially:The left side homology arm that will be expanded
B739_1343-L carries out double digestion with BamHI, NheI, and the right side homology arm B739_1343-R of amplification is entered with EcoRI, KpnI
Row double digestion, double digestion is carried out by the Spec sequences of amplification with NheI, EcoRI;Will reclaim three fragment B739_1343-L,
Spec, B739_1343-R are connected overnight;Then with connection product as mould, with primer B739_1343-L F, B739_1343-R R
Amplification B739_1343-LSR fragments.
Further, step 3) in structure recombination suicide vector pEX18GM Δs B739_1343-LSR be specially:Will
The B739_1343-LSR fragments and plasmid pEX18GM of amplification carry out double digestion with BamHI and KpnI, the fragment and matter that will be reclaimed
Grain is connected overnight with T4 ligases, and connection product is transformed into Escherichia coli XL1-Blue competence, is coated big mould containing celebrating
The LB flat boards of element are screened;The monoclonal that will be obtained enters performing PCR identification, filters out and contains plasmid pEX18GM Δs B739_
The positive colony of 1343-LSR;Take out kit extracting recombinant plasmid and carry out digestion identification using plasmid is small;To identify correct
Recombinant plasmid transformed is in S17-1 Escherichia coli.
Further, step 4) in structure RA-CH-1B739_1343 gene-deleted strains be specially:By Escherichia coli
S17-1pEX18GM Δs B739_1343-LSR is inoculated in the LB fluid nutrient mediums of 10mL, and RA-CH-1 is lined containing 5% degreasing
In the LB solid mediums of sheep blood, 37 DEG C of cultures to exponential phase;Scraping RA-CH-1 is 10mmol/mL's in 1mL concentration
MgSO4In solution, then use MgSO4Solution is washed 2 times;Calculate donor bacterium S17-1pEX18GM Δs B739_1343-LSR up to 2.5 × 108
Individual bacterium number, recipient bacterium CH-1 is up to 109Volume required for individual bacterium number;Donor bacterium, recipient bacterium are mixed according to the volume for calculating, then
Filtered in injection filter;Remove filter membrane to be laid on blood plate, 30 DEG C of 5%CO2Culture 8h;By the bacterium MgSO on filter membrane4It is molten
Liquid is eluted, and it is on the blood plate containing the spectinomycin that kanamycins and concentration are 80 μ g/mL of 50 μ g/mL to coat concentration
Cultivated;The monoclonal of picking growth enters performing PCR identification, and structure obtains riemerella anatipestifer gene delection low virulent strain.
Further, PCR authentication methods are as follows:
A) using RA-CH-1 conserved sequence primer 16s rRNA F/R, PCR expands the 16s rRNA fragments of RA-CH-1, root
Judge whether Candidate Mutant strain is RA-CH-1 according to electrophoresis result;If the band that electrophoresis is obtained expands with by template of wild strain CH-1
Increase the stripe size for consistent, judge that Candidate Mutant strain is RA-CH-1 accordingly, wherein, the nucleotide sequence of 16s rRNA F
As shown in SEQ ID NO.11;The nucleotide sequence of 16s rRNA R is as shown in SEQ ID NO.12;
B) using the primer Spec P1/P2 of Spec resistant genes, Spec resistance gene fragments are expanded, according to electrophoresis result
Judge whether the replacement of producer;If the band that electrophoresis is obtained is in the same size with positive control, and is with wild strain RA-CH-1
Template fails to amplify band, judges that Spec genes have been substituted into Candidate Mutant pnca gene group accordingly;The nucleosides of Spec F
Acid sequence is as shown in SEQ ID NO.13;The nucleotide sequence of Spec R is as shown in SEQ ID NO.14;
C) utilize whether primer B739_1343F/R, amplifying target genes detect B739_1343 genes according to electrophoresis result
Lacked;If failing to amplify band by template of Candidate Mutant strain RA-CH-1 Δs B739_1343, it is with wild strain RA-CH-1
The band that template amplification is obtained, and it is in the same size with purpose band expection, the gene B739_1343 of Candidate Mutant strain is judged accordingly
Lacked;Wherein, the nucleotide sequence of B739_1343F is as shown in SEQ ID NO.15;The nucleotide sequence of B739_1343R
As shown in SEQ ID NO.16;
D) primer SacB F/R are utilized, is expanded, detect whether suicide vector is thrown out of genome according to electrophoresis result;
If in the same size with the expection of SacB genes with the band that plasmid pEX18GM is obtained as template amplification, and dashed forward with RA-CH-1, candidate
Mutant RA-CH-1 Δs B739_1343 fails to amplify band for template, judges that suicide vector is thrown out of genome accordingly;Wherein,
The nucleotide sequence of SacB F is as shown in SEQ ID NO.17;The nucleotide sequence of SacB R is as shown in SEQ ID NO.18.
The weak poison of Riemerlla anatipestifer is being prepared the invention also discloses a kind of riemerella anatipestifer gene delection low virulent strain
Application in vaccine.
Further, low virulent strain RA-CH-1 Δs B739_1343 is to dosage>100×LD50Wild virulent strain RA-CH-1
Attack malicious protective rate up to 83.33%, can be used as the candidate strain of RA gene-deleted vaccines.
Compared with prior art, the present invention can be obtained including following technique effect:
1) the low virulent strain Riemerella anatipestifer CH-1 Δs B739_1343 that the present invention builds is to wild type
Velogen strain attacks malicious protective rate up to 83.33%, can used as the candidate of RA gene-deleted vaccines.
2) present invention sets about from the Nutrition and Metabolism mechanism of pathogen, constructs pnca gene missing low virulent strain, is subsequently to open
The vaccine for sending out new is ensured there is provided recent studies on methods and techniques.
Certainly, implement any product of the invention to it is not absolutely required to while reaching all the above technique effect.
Brief description of the drawings
Accompanying drawing described herein is used for providing a further understanding of the present invention, constitutes a part of the invention, this hair
Bright schematic description and description does not constitute inappropriate limitation of the present invention for explaining the present invention.In the accompanying drawings:
Fig. 1 is PCR amplifications B739_1343 genes of the present invention or so homology arm and Spec resistant gene amplifications;Wherein,
M:Mark, 1:The left side homology arm B739_1343-L of amplification, 2:The right side homology arm B739_1343-R of amplification, 3:Amplification
Spec resistance gene sequences;
Fig. 2 is that recombination suicide vector pEX18GM Δs B739_1343-LSR of the present invention builds schematic diagram;
Fig. 3 is that RA-CH-1 Δs B739_1343 gene-deleted strains of the present invention build identification;Wherein, M:mark;1,2 represents amplification
The conserved sequence of RA-CH-1, RA-CH-1 Δ B739_1343;The 3 Spec sequences for representing amplification, are positive control;4,5 represent expansion
The Spec sequences of RA-CH-1, RA-CH-1 Δ B739_1343 of increasing;6,7 RA-CH-1, RA-CH-1 Δ B739_ for representing amplification
1343 B739_1343 sequences;The 8 SacB sequences for representing amplification, are positive control;9,10 RA-CH-1, RA- for representing amplification
The SacB sequences of CH-1 Δs B739_1343;
Fig. 4 is that RA-CH-1 Δ B739_1343 low virulent strains attack duckling survival rate statistics knot in malicious Protection in the present invention
Really.
Specific embodiment
Describe embodiments of the present invention in detail below in conjunction with embodiment, thereby to the present invention how application technology hand
Section can fully understand and implement according to this to solve technical problem and reach the implementation process of technology effect.
The structure side of embodiment 1Riemerella anatipestifer CH-1 Δ B739_1343 gene delection low virulent strains
Method
1) the PCR amplifications of RA-CH-1B739_1343 genes or so homology arm and Spec resistant genes:
The nucleotide sequence of B739_1343 genes left side homology arm B739_1343-L as shown in SEQ ID NO.2, B739_
The nucleotide sequence of 1343 gene right homology arm B739_1343-R as shown in SEQ ID NO.3, the nucleosides of Spec resistant genes
Acid sequence is as shown in SEQ ID NO.4.
Two couples of primers (B739_1343-L F/R, B739_1343-R are designed according to B739_1343 genes or so homology arm
), F/R and in primer 5 '-end addition restriction enzyme digestion sites.
B739_1343-L F:CGGGATCCCGGTACCACCTTGGTTAATAATATTC, its nucleotide sequence such as SEQ ID
It is BamHI in primer 5 '-end addition restriction enzyme digestion sites shown in NO.5;
B739_1343-L R:CTAGCTAGCTAGTCCAATCCAGATTGATTTC, its nucleotide sequence such as SEQ ID
It is NheI in primer 5 '-end addition restriction enzyme digestion sites shown in NO.6;
B739_1343-R F:CGGAATTCCGCTATTAACATTTTTAATTAAAAC, its nucleotide sequence such as SEQ ID
It is EcoRI in primer 5 '-end addition restriction enzyme digestion sites shown in NO.7;
B739_1343-R R:GGGGTACCCCTACTTAGAGAGCGTACAGCTCC, its nucleotide sequence such as SEQ ID
It is KpnI in primer 5 '-end addition restriction enzyme digestion sites shown in NO.8;
By the use of RA-CH-1 genomes as template, respectively with B739_1343-L F/R and B739_1343-R F/R to draw
Thing amplification B739_1343 genes or so homology arm fragment B739_1343-L and B739_1343-R.PCR conditions are:98 DEG C of denaturation
30s, through 98 DEG C of 10s, 55 DEG C of 30s, 72 DEG C of 30s cyclic amplifications 30 times, 72 DEG C of extension 7min.Electrophoresis result shows that amplification obtains two
The band (see Fig. 1) of treaty 800bp, it is in the same size with expected B739_1343-L and B739_1343-R.
Spec resistance gene fragments design primer Spec F/R in plasmid pAM238, and added at primer 5 '-end
NheI, EcoRI restriction enzyme site.
Spec F:CTAGCTAGCTAGCTCGACTTCGCTGCTGCCC, its nucleotide sequence as shown in SEQ ID NO.9,
And add NheI restriction enzyme sites at primer 5 '-end;
Spec R:CGGAATTCCGCGAATTGTTAGACATTATTTG, its nucleotide sequence such as SEQ ID NO.10 institutes
Show, and EcoRI restriction enzyme sites are added at primer 5 '-end;
By the use of plasmid pAM238 as template, Spec sequences are expanded by primer PCR of Spec F/R.PCR conditions are:98℃
Denaturation 30s, through 98 DEG C of 10s, 55 DEG C of 30s, 72 DEG C of 50s cyclic amplifications 30 times, 72 DEG C of extension 7min.Electrophoresis result shows to expand
To the band (see Fig. 1) of a treaty 1200bp, it is expected with Spec resistance gene fragments in the same size.
2) structure of B739_1343-LSR fragments
The left side homology arm B739_1343-L of amplification is carried out into double digestion with BamHI, NheI, the right side that will be expanded is homologous
Arm B739_1343-R carries out double digestion with EcoRI, KpnI, and the Spec sequences of amplification are carried out into double digestion with NheI, EcoRI.
Three fragments B739_1343-L, Spec, the B739_1343-R connections that will be reclaimed are overnight.Then it is with connection product
Mould, B739_1343-LSR fragments are expanded with primer B739_1343-L F, B739_1343-R R.
3) recombination suicide vector pEX18GM Δs B739_1343-LSR is built
The B739_1343-LSR fragments and plasmid pEX18GM of amplification are carried out into double digestion with BamHI and KpnI, will be reclaimed
Fragment and plasmid with T4 ligases connect overnight, connection product is transformed into Escherichia coli XL1-Blue competence, be coated with
Screened in the LB flat boards containing gentamicin.
The monoclonal that will be obtained enters performing PCR identification, filters out the positive containing plasmid pEX18GM Δs B739_1343-LSR
Clone.Take out kit extracting recombinant plasmid and carry out digestion identification using plasmid is small.To identify that correct recombinant plasmid transformed is arrived
In S17-1 Escherichia coli.Recombination suicide vector pEX18GM Δs B739_1343-LSR builds schematic diagram and sees Fig. 2.
4) structure of RA-CH-1 B739_1343 gene-deleted strains
The present invention uses mating transfer method, with Escherichia coli S17-1 pEX18GM Δs B739_1343-LSR as confession
Body bacterium, RA-CH-1 carries out engagement transfer for recipient bacterium, comprises the following steps that:
Escherichia coli S17-1 pEX18GM Δs B739_1343-LSR is inoculated in the LB fluid nutrient mediums of 10mL, RA-
CH-1 is lined in the LB solid mediums (blood plate) containing 5% degreasing sheep blood, 37 DEG C of cultures to exponential phase;Scraping RA-
CH-1 is the MgSO of 10mmol/mL in 1mL concentration4In solution, then use MgSO4Solution is washed 2 times;Calculate donor bacterium S17-
1pEX18GM Δs B739_1343-LSR is up to 2.5 × 108Individual bacterium number, recipient bacterium RA-CH-1 is up to 109Volume required for individual bacterium number;
Donor bacterium, recipient bacterium are mixed according to the volume for calculating, is then injected into being filtered in filter;Remove filter membrane to be laid on blood plate, 30
DEG C 5%CO2Culture 8h;By the bacterium MgSO on filter membrane4Eluant solution gets off, and coats containing kanamycins (50 μ g/mL) and strengthens
Cultivated on the blood plate of miromycin (80 μ g/mL);The monoclonal of picking growth enters performing PCR identification.
The step of PCR is identified be:
A) using RA-CH-1 conserved sequence primer 16s rRNA F/R, PCR expands the 16s rRNA fragments of RA-CH-1
(960bp), judges whether Candidate Mutant strain is RA-CH-1.Electrophoresis result shows with Candidate Mutant strain (RA-CH-1 Δs B739_
1343) band (see Fig. 3) of a treaty 1000bp is obtained for template amplification, with the band gone out as template amplification with wild strain CH-1
It is in the same size, judge that Candidate Mutant strain is RA-CH-1 accordingly;
Wherein, 16s rRNA F/R include 16s rRNA F and 16s rRNA R, 16s rRNA F:
CTTCGGATACTTGAGAGCG, its nucleotide sequence is as shown in SEQ ID NO.11;16s rRNA R:
GCAGCACCTTGAAAATTGT, its nucleotide sequence is as shown in SEQ ID NO.12;
B) using the primer Spec P1/P2 of Spec resistant genes, amplification Spec resistance gene fragments (1140bp) judges
Whether the replacement of producer.Electrophoresis result shows with Candidate Mutant strain (RA-CH-1 Δ B739_1343) as template amplification is obtained
The band (see Fig. 3) of one treaty 1000bp, it is in the same size with positive control, and fail amplification by template of wild strain RA-CH-1
Shaping band, judges that Spec genes have been substituted into Candidate Mutant pnca gene group accordingly;
Wherein, Spec P1/P2 include Spec P1 and Spec P2, Spec P1:CTCGACTTC GCTGCTGCCC, its core
Nucleotide sequence is as shown in SEQ ID NO.13;Spec P2:CGAAT TGTTAGACATTATTTG, its nucleotide sequence such as SEQ
Shown in ID NO.14;
C) primer B739_1343F/R is utilized, amplifying target genes are detecting whether B739_1343 genes are lacked.Electrophoresis
Result shows with Candidate Mutant strain (RA-CH-1 Δ B739_1343) as template fails to amplify band, with wild strain RA-CH-1
The band (see Fig. 3) of a treaty 2000bp is obtained for template amplification, it is in the same size with purpose band expection, judge that candidate dashes forward accordingly
The gene B739_1343 of mutant is lacked.
Wherein, B739_1343F:CATGCCATGGATGATGCTGTTTTTCAGCACCG, its nucleotide sequence such as SEQ ID
Shown in NO.15;B739_1343R:CTAGTCTAGATTAA AAATTAAATTGACAAGTG, its nucleotide sequence such as SEQ ID
Shown in NO.16;
D) primer SacB F/R are utilized, is expanded to detect whether suicide vector is thrown out of genome;Electrophoresis result table
It is bright to obtain an about band of 1000bp by template amplification of plasmid pEX18GM, it is in the same size with the expection of SacB genes, and with
RA-CH-1, Candidate Mutant strain (RA-CH-1 Δ B739_1343) fail to amplify band (see Fig. 3) for template, judge accordingly certainly
Kill carrier and be thrown out of genome.
Wherein, SacB F:CATGCCATGGATGAACATCAAAAAGTTTGC, its nucleotide sequence such as SEQ ID NO.17
It is shown;SacB R:CTAGTCTAGACTAGTTATTTGTT AACTGTTAATTGTCCTTGTTCAAGG, its nucleotide sequence is such as
Shown in SEQ ID NO.18.
Whether the detection of embodiment 2 gene-deleted strain RA-CH-1 Δs B739_1343 weakens to the virulence of duckling
Determine the LD of RA-CH-1 Δ B739_1343 gene-deleted strains50Value.Comprise the following steps that:
RA-CH-1, RA-CH-1 Δ B739_1343 gene-deleted strains are inoculated in TSB respectively, 37 DEG C of 180rpm shaken cultivations
To exponential phase.Collects thalline under normal temperature, is washed 3 times with PBS, determines bacterium solution OD600Value.It is ready for bacterium solution dense to following 4
Degree gradient:5×1010CFU/mL、5×109CFU/mL、5×108CFU/mL、5×107CFU/mL。
3 age in days Beijing ducks are divided into 4 groups, every group 10, every is inoculated with 0.2mL bacterium solutions through intramuscular injection path, attacks toxic agent
Amount is respectively 1010CFU、109CFU、108CFU、107CFU.Observed and recorded attacks duck survival condition in malicious one week after.By Reed-
Muench methods calculate median lethal dose.
As a result:The LD of RA-CH-1 Δ B739_1343 gene-deleted strains50Value is more than 1010The LD of CFU, RA-CH-150Value is about
108CFU (is shown in Table 1);RA-CH-1 Δ B739_1343 gene-deleted strains have dropped at least 100 times to the pathogenicity of duckling.
Table 1RA-CH-1 Δ B739_1343 gene-deleted strains LD50Measurement result
Embodiment 3 provides applications of the low virulent strain RA-CH-1 Δs B739_1343 as gene delection candidate vaccine
1) preparation of gene delection candidate vaccine:
Low virulent strain RA-CH-1 Δs B739_1343 is cultivated to exponential phase, bacteria containing amount is diluted to after collects thalline and is about 5
×108CFU/mL。
2) immunisation route and dosage:
Through leg muscle injecting immune, only, immunizing dose is about 10 to 0.2ml/ to 3 age in days ducklings8CFU。
3) the safety examination result of the gene delection low virulent strain is provided:
The clinical manifestation of duckling and changes of weight are immunized low virulent strain RA-CH-1 Δs as evaluation index after being immunized
B739_1343 groups and non-immunized controls group substantially indifference.
4) immune protective effect of the gene delection low virulent strain is provided:
The low virulent strain to high dose (>100×LD50) wild virulent strain RA-CH-1 attacks malicious protective rate up to 83.33%, and
And the duck of the survival of immune RA-CH-1 Δ B739_1343 groups can normally search for food, drink water with inactivated vaccine group, spirit well,
The basic indifference of body weight increment.
Embodiment 4RA-CH-1 Δ B739_1343 low virulent strains as gene delection candidate vaccine evaluation
Safety examination after the immune duckling of RA-CH-1 Δ B739_1343 low virulent strains is determined with malicious protection is attacked.
Selection Beijing duck is animal model, low dosage through the immune RA-CH-1 Δ B739_1343 of intramuscular injection, then with wild
Strain RA-CH-1 attacks poison, to determine and attack malicious protection after immune low virulent strain RA-CH-1 Δs B739_1343.Comprise the following steps that:
1) low virulent strain RA-CH-1 Δs B739_1343 is inoculated in TSB, 37 DEG C of 180rpm shaken cultivations to logarithmic growth
Phase.
2) under normal temperature, 6500rmp is collected by centrifugation thalline, is washed 3 times with PBS, and bacterium solution OD is determined after dilution600Value.
3) according to the OD for determining600Value, dilution RA-CH-1 Δs B739_1343 is about 5 × 10 to concentration8CFU/mL。
4) 3 age in days Beijing ducks are divided into 4 groups, every group 20.First group of I makees through leg muscle injection 0.2mL sterilizing PBS
It is negative control;Second group of II is about 5 × 10 through leg muscle injection 0.2mL concentration8The RA-CH-1 Δs B739_ of CFU/mL
1343, immunizing dose is about 108CFU;3rd group of III through neck hypodermic injection 0.25mL commodity inactivated vaccine, (give birth to by Chengdu day nation
Tetramune Co., Ltd, slurry profit is good), as positive control;4th group of IV is not immunized and does not attack poison, used as blank.Monitoring is exempted from
The clinical manifestation of duck after epidemic disease, while the body weight of each group duck is weighed, the safety of assessment low virulent strain RA-CH-1 Δs B739_1343
Property.
5) head exempt from rear 12d to first group of I, second group of II, the 3rd group of III RA-CH-1 bacterium solution through leg injection attack poison, join
According to the LD for determining before50Value, attacks toxic agent amount for every and is about 2.28 × 1010(>100×LD50).Duck in 10 days is attacked after poison in monitoring
Health condition and changes of weight.
As a result:
Safety examination after the immune duckling of RA-CH-1 Δ B739_1343 low virulent strains:Before poison is attacked, RA-CH-1 is immunized
Δ B739_1343 groups and other three groups of duck average weight no significant differences, and duck feeding, drinking-water, mental status etc. face
Bed feature is acted normally (be shown in Table 2), shows that the low virulent strain has no effect on the growth performance of duck, using upper safe and reliable.
Duck body weights and clinical manifestation during the observation of table 2
Wherein, group I represents immune PBS groups, and group II represents immune RA-CH-1 Δ B739_1343 groups, group III generations
The immune commodity inactivated vaccine group of table, group IV represents blank control group.
Malicious protection measurement result is attacked after the immune duckling of RA-CH-1 Δ B739_1343 low virulent strains:RA-CH-1 attacks poison
Afterwards, commodity inactivated vaccine group and blank control group duck survival rate are 100%;RA-CH-1 Δ B739_1343 immune group survival rates are
85%;PBS groups survival rate is 25% (see Fig. 3).The duck performance of PBS groups survival is become thin, drowsiness, nervous symptoms etc., and is immunized
The duck of the survival of RA-CH-1 Δ B739_1343 groups can normally search for food, drink water with inactivated vaccine group, blank control group, spirit
Well, and body weight is rised in value basic indifference (being shown in Table 2).RA-CH-1 Δ B739_1343 low virulent strains are attacked poison protection result and show weak poison
Strain to high dose (>100×LD50) wild type velogen strain RA-CH-1 attacks malicious protective rate up to 83.33% (being shown in Table 3).
RA-CH-1 Δs B739_1343 low virulent strains attack malicious protection measurement result in the present invention of table 3
Wherein, the immunizing dose of RA-CH-1 Δs B739_1343 is about 10 in group II8CFU。
Result above shows that the low virulent strain is upper safe and reliable in application, and malicious protecting effect is attacked with higher, can be used as grinding
The candidate strain of the gene-deleted vaccine for sending out new.
Described above has shown and described some preferred embodiments of invention, but as previously described, it should be understood that invention is not
Form disclosed herein is confined to, the exclusion to other embodiment is not to be taken as, and can be used for various other combinations, modification
And environment, and can be carried out by the technology or knowledge of above-mentioned teaching or association area in invention contemplated scope described herein
Change.And the change and change that those skilled in the art are carried out do not depart from the spirit and scope of invention, then all should be in the appended power of invention
In the protection domain that profit is required.
SEQUENCE LISTING
<110>Sichuan Agricultural University
<120>One plant of riemerella anatipestifer gene delection low virulent strain and its construction method and application
<130> 2016
<160> 18
<170> PatentIn version 3.5
<210> 1
<211> 2352
<212> DNA
<213>Ferroheme movement system B739_1343 genes
<400> 1
atgatgctgt ttttcagcac cgttctaaat gcacagcttt accttataga aggtcaggta 60
agagatttgc acgacaatac acctttagct aatgctaaaa taagtattaa cggaaaactc 120
attaccactt ctgatactca aggaaatttt aatttttctt acaaaaaagg cactcatcat 180
cttttgataa cccacttaga ttgtgaacct tttactaaaa agataatact tgatagaaat 240
attaaaatca acattttcct tgagcatcat actaatgaaa tagaaaccgt agtagtacat 300
ggcattcata aaaagtcagg gacggcggtt atcaaaacat tagaacagtc ttttttagag 360
caaaaaacta ccgaaaatct aggcaacata ttgtctgaaa tttctggagt aaatagtatt 420
aaaacaggga ataacatttc taaacctgtt atacaaggac tttacggcag tagagtgttg 480
gtaatgaaca acggcatcaa aatggcagaa caagaatggg gcatagaaca cgctcctagc 540
gtggatccca acgcttttga ccatatagat gttgtaaagg gagcatctgc actaaagtac 600
ggtggagatg ccataggtgg cgttatacta ttagaaagtc ctaaataccc taaaaaagac 660
acccttatgg gtaaagtagc tttatcaggc atcagcaatg gtaaaggctt ggctctgaat 720
acggacatta caaagacttg gcaaaacggt tgggctttgc ggacgcaagg ttctgccaaa 780
aagctaggag atttggaaac acccaattat agtttacaaa atacgggtgc agatgaaaac 840
gcctcccact tttccctaca aaaaagggaa tacgaatacg gaatcacggc taaatattct 900
ttcatcaacc aaaattttgg aatttataaa ggggctcata tcagtaatgc aagaaacttt 960
gccgatgcca tcaataacgg acaatcctac tttacaggta attttggtta taaaatagag 1020
aatcctaaac aagaagttag ccatcacatt gctaaattgg aggcttacaa aagattagga 1080
aggctaggaa aatttacttt agaatatgcc tttcagcaaa atcatagatt tgaatacgat 1140
attcgtagag gagcgtacaa tgataaacct gctaccgacc tactactaac cacccaaagt 1200
ttggctcttt atcatctatt agaaagaccc aactggcagt gggaaacagg tctatcagga 1260
aattatcaag ttaattttcc cgacccaaaa acggagcgtt ctcgtttaat accagattac 1320
cataggtatg atgctggtgc tttttctatt ttcaaatatc aaaaaaatct ttggaaatgg 1380
gaagcagctt tgcggtacga tatgaatttc tacgatgtgt ataaatatta ccttaataaa 1440
gattgggcag cttacagcca agcgtttcat caatttgtaa ttgaaagtaa aggagtgaaa 1500
acattggtgc gtccaaaact ttattaccat aatatatcag catcgttggg tatggaatat 1560
cagcccactc gctttcttac taccaaattt aatttgataa gaaatagccg aagtcctaat 1620
gttgcagaat tattcgctga tgggctacac cacgctgctg ccattattga aaagggagat 1680
atgactatca aaaacgagga aacctaccaa gcccacctaa gcattggtat aaaagcctcc 1740
gttcttaatg gttttaaact taatcttaat ccgtattatt tcacttccga tagttttatt 1800
aaccaaacac ctaacggagt ggaaagtacc attcgtggga atttccctgt atggcaatat 1860
caacagatta aagccaaaat gtatgggata gacatagatt cagaacttaa catcactcca 1920
aaattacaat ggaatggagc gatgagctat gtgtacggac aagacttaac ccataatgaa 1980
cccttgatac ttatgcctcc aatgcagatt aaaaacgccc taagatatga taacaaaggt 2040
aaaaaaccgt ggcatataca aatagaaaac ctagtggtat ttaagcagaa aagatttcct 2100
atgaggcttt tatcctacga tgtatatgag aacaatacaa taaccaaaga gtggctagac 2160
attagtacac cacccgcagg ttatcaaatt tggaacctca atgctggagc aaagctcact 2220
agaaacattc agcttaattt gagtgttaat aatatattca atacaactta tagagaatat 2280
cttaaccgtt tgagattttt ctctgatgct ttgggacgaa atattatttt cacttgtcaa 2340
tttaattttt aa 2352
<210> 2
<211> 796
<212> DNA
<213>B739_1343 genes left side homology arm sequence
<400> 2
gtaccacctt ggttaataat attcttaaca gacctaggtc ccattttaat catgttccct 60
tctataagcc cattgtaccc ttctctaatc cccatacatt ctataccata ataatgagct 120
gttcttacca ctgcccttat cgccgcattc atacctggag aatcccctcc agaagtaaga 180
actcctatcc ttttcaactt tgattctgac ataattaaat actttttagc ctagcaaata 240
taagaaattt taactacatt attttaagat ttatatcata ttattactcc tacatctatt 300
cattacatgt tcatttgtat cttagtaaat aaaagttttt ttacctttgc aaaatgtttt 360
cagggaaact tcttttcaga aaagttacaa gtataagcct tgcatgggtt tatgcattag 420
ctttactgat ggctagtgta ttccactcgc atcaagagac ttttaatagt aattataatt 480
cttcccaaaa acagaatcac aaaataatca gtttaaaggg agatgattgt tctatctgtc 540
attttttcat ttcagggcat tctctgcttc ccgaaaaggt aaactttgaa gttttagtat 600
cagtagctac tacacttata ataggctaca agacactgga catccttcag aatcaaattg 660
tttatttctt acttagagga ccgccttcta ttttatagaa ataatatcat tttcactagg 720
tgttctaccg ttttgttagg acacggtttt aaccttttaa ttttcatatc tttaaatgaa 780
atcaatctgg attgga 796
<210> 3
<211> 803
<212> DNA
<213>B739_1343 gene right homology arm sequences
<400> 3
ctattaacat ttttaattaa aacaatttta aaacattatg aaacattcat ttttaaaaac 60
cgcagtatta tccgcagtaa gtattttagc cctcaactct tgtagagata atgatgaagc 120
acctgccgat gtacacaacc acgacgaagt acaatacctt accgttacac ttaccaatac 180
tgctgataac agcacccaaa ccgctacatt cagtgcagaa ggagctgata aagagttagt 240
tttaaaagaa aacaacactt atgatgttca gttatcatta gtagctcctc atgacgacca 300
tacccacgat gttactgatg aaatcataga actaaaagag gaacattttt tcacttataa 360
tttctctaat gtagatgtta aagttactag aaaagatgaa gctgaaagca ctagaaaaga 420
tgggtctaaa ataggtctaa aaacacagtg gcaagtaaca tctgcaccaa aaacaggagc 480
taaagctaac attagacttt accaccttcc tacctctgtg aaaatgagcg gtgctaatgg 540
agacgaagca ggaactgtaa caggtggtga agaggatatt gatgctactt ttaatgttaa 600
ataatgaaat atatctatgt agacacagat attgatactt taatatgatg tttaactcaa 660
aaaatcaaac aaaatgaaaa aagtattttt actaggagca ttagctctgt acagtgctac 720
aaatgcacaa cttaaatttg gtggaaaagc aggatacgcc ttatccgaag tcggagatac 780
aggagctgta cgctctctaa gta 803
<210> 4
<211> 1140
<212> DNA
<213>Spec resistant genes
<400> 4
ctcgacttcg ctgctgccca aggttgccgg gtgacgcaca ccgtggaaac ggatgaaggc 60
acgaacccag tggacataag cctgttcggt tcgtaagctg taatgcaagt agcgtatgcg 120
ctcacgcaac tggtccagaa ccttgaccga acgcagcggt ggtaacggcg cagtggcggt 180
tttcatggct tgttatgact gtttttttgg ggtacagtct atgcctcggg catccaagca 240
gcaagcgcgt tacgccgtgg gtcgatgttt gatgttatgg agcagcaacg atgttacgca 300
gcagggcagt cgccctaaaa caaagttaaa catcatgagg gaagcggtga tcgccgaagt 360
atcgactcaa ctatcagagg tagttggcgt catcgagcgc catctcgaac cgacgttgct 420
ggccgtacat ttgtacggct ccgcagtgga tggcggcctg aagccacaca gtgatattga 480
tttgctggtt acggtgaccg taaggcttga tgaaacaacg cggcgagctt tgatcaacga 540
ccttttggaa acttcggctt cccctggaga gagcgagatt ctccgcgctg tagaagtcac 600
cattgttgtg cacgacgaca tcattccgtg gcgttatcca gctaagcgcg aactgcaatt 660
tggagaatgg cagcgcaatg acattcttgc aggtatcttc gagccagcca cgatcgacat 720
tgatctggct atcttgctga caaaagcaag agaacatagc gttgccttgg taggtccagc 780
ggcggaggaa ctctttgatc cggttcctga acaggatcta tttgaggcgc taaatgaaac 840
cttaacgcta tggaactcgc cgcccgactg ggctggcgat gagcgaaatg tagtgcttac 900
gttgtcccgc atttggtaca gcgcagtaac cggcaaaatc gcgccgaagg aggtcgctgc 960
cgactgggca atggagcgcc tgccggccca gtatcagccc gtcatacgtg aagctagaca 1020
ggcttatctt ggacaagaag aagatcgctt ggcctcgcgc gcagatcagt tggaagaatt 1080
tgtccactac gtgaaaggcg agatcaccaa ggtagtcggc aaataatgtc taacaattcg 1140
<210> 5
<211> 34
<212> DNA
<213>Artificial sequence
<400> 5
cgggatcccg gtaccacctt ggttaataat attc 34
<210> 6
<211> 31
<212> DNA
<213>Artificial sequence
<400> 6
ctagctagct agtccaatcc agattgattt c 31
<210> 7
<211> 33
<212> DNA
<213>Artificial sequence
<400> 7
cggaattccg ctattaacat ttttaattaa aac 33
<210> 8
<211> 32
<212> DNA
<213>Artificial sequence
<400> 8
ggggtacccc tacttagaga gcgtacagct cc 32
<210> 9
<211> 31
<212> DNA
<213>Artificial sequence
<400> 9
ctagctagct agctcgactt cgctgctgcc c 31
<210> 10
<211> 31
<212> DNA
<213>Artificial sequence
<400> 10
cggaattccg cgaattgtta gacattattt g 31
<210> 11
<211> 19
<212> DNA
<213>Artificial sequence
<400> 11
cttcggatac ttgagagcg 19
<210> 12
<211> 19
<212> DNA
<213>Artificial sequence
<400> 12
gcagcacctt gaaaattgt 19
<210> 13
<211> 19
<212> DNA
<213>Artificial sequence
<400> 13
ctcgacttcg ctgctgccc 19
<210> 14
<211> 21
<212> DNA
<213>Artificial sequence
<400> 14
cgaattgtta gacattattt g 21
<210> 15
<211> 32
<212> DNA
<213>Artificial sequence
<400> 15
catgccatgg atgatgctgt ttttcagcac cg 32
<210> 16
<211> 32
<212> DNA
<213>Artificial sequence
<400> 16
ctagtctaga ttaaaaatta aattgacaag tg 32
<210> 17
<211> 30
<212> DNA
<213>Artificial sequence
<400> 17
catgccatgg atgaacatca aaaagtttgc 30
<210> 18
<211> 48
<212> DNA
<213>Artificial sequence
<400> 18
ctagtctaga ctagttattt gttaactgtt aattgtcctt gttcaagg 48
Claims (9)
1. one plant of riemerella anatipestifer gene delection low virulent strain, it is characterised in that the bacterial strain is riemerella anatipestifer CH-1
Δ B739_1343, is named as Riemerella anatipestifer CH-1 Δ B739_1343, is protected within 30th in August in 2016
China typical culture collection center is hidden in, its preserving number is CCTCC NO:M2016438, the bacterial strain has lacked ferroheme transhipment
The 2352bp of system B7391343 genes, the gene order for being lacked is as shown in SEQ ID NO.1.
2. the construction method of riemerella anatipestifer gene delection low virulent strain, it is characterised in that comprise the following steps:
1) PCR amplifications RA-CH-1B739_1343 genes or so homology arm and Spec resistant genes;
2) the RA-CH-1B739_1343 genes that will have been expanded or so homology arm and Spec resistant genes carry out digestion and connected
At night, build B739_1343-LSR fragments;
3) recombination suicide vector pEX18GM Δs B739_1343-LSR is built;
4) RA-CH-1B739_1343 gene-deleted strains are built, RA-CH-1B739_1343 gene-deleted strains are Mo Shi in pest of duck
Bacillus gene lacks low virulent strain.
3. the construction method of riemerella anatipestifer gene delection low virulent strain according to claim 2, it is characterised in that institute
The step of stating 1) in PCR amplification RA-CH-1B739_1343 genes or so homology arms and Spec resistant genes be specially:
1.1) two couples of primer B739_1343-L F/R and B739_1343-R are designed according to B739_1343 genes or so homology arm
F/R, and in primer 5 '-end addition restriction enzyme digestion sites;By the use of RA-CH-1 genomes as template, respectively with
B739_1343-L F/R and B739_1343-R F/R are primer amplification B739_1343 genes or so homology arm fragment B739_
1343-L and B739_1343-R;PCR conditions are:98 DEG C of denaturation 30s, through 98 DEG C of 10s, 55 DEG C of 30s, 72 DEG C of 30s cyclic amplifications 30
It is secondary, 72 DEG C of extension 7min;
Wherein, B739_1343-L F/R include B739_1343-L F and B739_1343-L R,
The nucleotide sequence of B739_1343-L F adds restriction enzyme as shown in SEQ ID NO.5 at primer 5 '-end
Restriction enzyme site is BamHI;The nucleotide sequence of B739_1343-L R is added as shown in SEQ ID NO.6 at primer 5 '-end
Restriction enzyme digestion sites are NheI;
B739_1343-R F/R include the nucleotide sequence of B739_1343-R F and B739_1343-R R, B739_1343-RF
As shown in SEQ ID NO.7, and it is EcoRI in primer 5 '-end addition restriction enzyme digestion sites;B739_1343-R R
Nucleotide sequence as shown in SEQ ID NO.8, and be KpnI in primer 5 '-end addition restriction enzyme digestion sites;
1.2) the Spec resistance gene fragments design primer Spec F/R in plasmid pAM238, and added at primer 5 '-end
NheI, EcoRI restriction enzyme site;By the use of plasmid pAM238 as template, Spec sequences are expanded by primer PCR of Spec F/R;PCR
Condition is:98 DEG C of denaturation 30s, through 98 DEG C of 10s, 55 DEG C of 30s, 72 DEG C of 50s cyclic amplifications 30 times, 72 DEG C of extension 7min;
Wherein, Spec F/R include the nucleotide sequence of Spec F and Spec R, Spec F as shown in SEQ ID NO.9, and
Primer 5 '-end adds NheI restriction enzyme sites;The nucleotide sequence of Spec R as shown in SEQ ID NO.10, and at primer 5 '-end
Add EcoRI restriction enzyme sites.
4. the construction method of riemerella anatipestifer gene delection low virulent strain according to claim 3, it is characterised in that institute
The step of stating 2) in structure B739_1343-LSR fragments be specially:The left side homology arm B739_1343-L that will be expanded is used
BamHI, NheI carry out double digestion, and the right side homology arm B739_1343-R of amplification is carried out into double digestion with EcoRI, KpnI, will expand
The Spec sequences of increasing carry out double digestion with NheI, EcoRI;Three fragments B739_1343-L, Spec, the B739_ that will be reclaimed
1343-R is connected overnight;Then with connection product as mould, B739_ is expanded with primer B739_1343-L F, B739_1343-R R
1343-LSR fragments.
5. the construction method of riemerella anatipestifer gene delection low virulent strain according to claim 4, it is characterised in that institute
The step of stating 3) in structure recombination suicide vector pEX18GM Δs B739_1343-LSR be specially:The B739_ that will be expanded
1343-LSR fragments and plasmid pEX18GM carry out double digestion with BamHI and KpnI, the fragment and plasmid T4 ligases that will be reclaimed
Connection overnight, connection product is transformed into Escherichia coli XL1-Blue competence, is coated the LB flat boards containing gentamicin and is entered
Row screening;The monoclonal that will be obtained enters performing PCR identification, filters out positive gram containing plasmid pEX18GM Δs B739_1343-LSR
It is grand;Take out kit extracting recombinant plasmid and carry out digestion identification using plasmid is small;To identify that correct recombinant plasmid transformed is arrived
In S17-1 Escherichia coli.
6. the construction method of riemerella anatipestifer gene delection low virulent strain according to claim 5, it is characterised in that institute
The step of stating 4) in structure RA-CH-1B739_1343 gene-deleted strains be specially:By Escherichia coli S17-1pEX18GM Δs
B739_1343-LSR is inoculated in the LB fluid nutrient mediums of 10mL, and RA-CH-1 lines the LB solids training containing 5% degreasing sheep blood
Support in base, 37 DEG C are cultivated to exponential phase;Scraping RA-CH-1 is the MgSO of 10mmol/mL in 1mL concentration4In solution, then use
MgSO4Solution is washed 2 times;Calculate donor bacterium S17-1pEX18GM Δs B739_1343-LSR up to 2.5 × 108Individual bacterium number, recipient bacterium RA-
CH-1 is up to 109Volume required for individual bacterium number;Donor bacterium, recipient bacterium are mixed according to the volume for calculating, mistake in filter is then injected into
Filter;Remove filter membrane to be laid on blood plate, 30 DEG C of 5%CO2Culture 8h;By the bacterium MgSO on filter membrane4Eluant solution gets off,
It is to be cultivated on the blood plate containing the spectinomycin that kanamycins and concentration are 80 μ g/mL of 50 μ g/mL to coat concentration;Choose
The monoclonal for taking growth enters performing PCR identification, and structure obtains riemerella anatipestifer gene delection low virulent strain.
7. the construction method of riemerella anatipestifer gene delection low virulent strain according to claim 6, it is characterised in that institute
The PCR authentication methods stated are as follows:
A) using RA-CH-1 conserved sequence primer 16s rRNA F/R, PCR expands the 16s rRNA fragments of RA-CH-1, according to electricity
Whether the Candidate Mutant strain of swimming result judgement is RA-CH-1;If the band that electrophoresis is obtained goes out with by template amplification of wild strain CH-1
Stripe size it is consistent, judge that Candidate Mutant strain is RA-CH-1 accordingly, wherein, the nucleotide sequence such as SEQ of 16s rRNA F
Shown in ID NO.11;The nucleotide sequence of 16s rRNA R is as shown in SEQ ID NO.12;
B) using the primer Spec P1/P2 of Spec resistant genes, Spec resistance gene fragments are expanded, is judged according to electrophoresis result
Whether the replacement of producer;If the band that electrophoresis is obtained is in the same size with positive control, and with wild strain RA-CH-1 as template
Fail to amplify band, judge that Spec genes have been substituted into Candidate Mutant pnca gene group accordingly;The nucleotides sequence of Spec F
Row are as shown in SEQ ID NO.13;The nucleotide sequence of Spec R is as shown in SEQ ID NO.14;
C) primer B739_1343F/R, amplifying target genes is utilized to detect whether B739_1343 genes are lacked according to electrophoresis result
Lose;If failing to amplify band by template of Candidate Mutant strain RA-CH-1 Δs B739_1343, with wild strain RA-CH-1 as template
The band that amplification is obtained, it is in the same size with purpose band expection, judge that the gene B739_1343 of Candidate Mutant strain is lacked accordingly
Lose;Wherein, the nucleotide sequence of B739_1343F is as shown in SEQ ID NO.15;The nucleotide sequence of B739_1343R such as SEQ
Shown in ID NO.16;
D) primer SacB F/R are utilized, is expanded, detect whether suicide vector is thrown out of genome according to electrophoresis result;If with
The band that plasmid pEX18GM is obtained for template amplification, it is in the same size with the expection of SacB genes, and with RA-CH-1, Candidate Mutant strain
RA-CH-1 Δs B739_1343 fails to amplify band for template, judges that suicide vector is thrown out of genome accordingly;Wherein, SacB
The nucleotide sequence of F is as shown in SEQ ID NO.17;The nucleotide sequence of SacB R is as shown in SEQ ID NO.18.
8. the riemerella anatipestifer gene delection low virulent strain described in claim 1 is preparing standby Riemerlla anatipestifer attenuated vaccine
In application.
9. application according to claim 8, it is characterised in that low virulent strain RA-CH-1 Δs B739_1343 is to dosage>100
×LD50Wild virulent strain RA-CH-1 attack malicious protective rate up to 83.33%, can used as the candidate bacterium of RA gene-deleted vaccines
Strain.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710022087.6A CN106701650B (en) | 2017-01-12 | 2017-01-12 | One plant of riemerella anatipestifer gene delection low virulent strain and its construction method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710022087.6A CN106701650B (en) | 2017-01-12 | 2017-01-12 | One plant of riemerella anatipestifer gene delection low virulent strain and its construction method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106701650A true CN106701650A (en) | 2017-05-24 |
CN106701650B CN106701650B (en) | 2019-11-08 |
Family
ID=58907460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710022087.6A Active CN106701650B (en) | 2017-01-12 | 2017-01-12 | One plant of riemerella anatipestifer gene delection low virulent strain and its construction method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106701650B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107964526A (en) * | 2017-10-12 | 2018-04-27 | 中国农业科学院上海兽医研究所 | The attenuation mutant of one plant of riemerella anatipestifer and its application |
CN110938577A (en) * | 2019-11-01 | 2020-03-31 | 四川农业大学 | Riemerella anatipestifer CH-1 strain fur gene deletion attenuated vaccine candidate strain, construction method and application |
-
2017
- 2017-01-12 CN CN201710022087.6A patent/CN106701650B/en active Active
Non-Patent Citations (3)
Title |
---|
CHUN,C.A等: "genbank:CP003787.1", 《NCBI》 * |
张洁: "鸭疫里默氏杆菌phoP基因鉴定及其突变株的免疫效果评价", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
税芸等: "鸭疫里默氏杆菌外膜血红素受体B739_1343的功能鉴定", 《爱学术》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107964526A (en) * | 2017-10-12 | 2018-04-27 | 中国农业科学院上海兽医研究所 | The attenuation mutant of one plant of riemerella anatipestifer and its application |
CN110938577A (en) * | 2019-11-01 | 2020-03-31 | 四川农业大学 | Riemerella anatipestifer CH-1 strain fur gene deletion attenuated vaccine candidate strain, construction method and application |
Also Published As
Publication number | Publication date |
---|---|
CN106701650B (en) | 2019-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110093324B (en) | Attenuated African swine fever virus with gene deletion and application thereof as vaccine | |
CN104862286B (en) | Porcine pseudorabies virus gene-deleted strain, vaccine composition and its preparation method and application | |
Seemüller et al. | Multiple infection of apple trees by distinct strains of ‘Candidatus Phytoplasma mali’and its pathological relevance | |
CN107815441A (en) | A kind of II type Pseudorabies virus attenuated strain and its preparation method and application | |
CN113862230B (en) | Porcine pseudorabies virus gene deletion strain, vaccine composition, preparation method and application thereof | |
CN105018433B (en) | Porcine pseudorabies virus gene-deleted strain, vaccine composition and its preparation method and application | |
CN108085302A (en) | Foot and mouth disease virus temperature sensitivity attenuated strain and its construction method and purposes | |
CN113943714B (en) | Callicarpa virus strain and application thereof | |
CN108884447A (en) | Coronavirus | |
Kim et al. | Development of duck hepatitis A virus type 3 vaccine and its use to protect ducklings against infections | |
CN110387355A (en) | Express recombinant porcine pseudorabies Strain, the vaccine and its preparation method and application of pig circular ring virus Cap protein gene | |
CN102776220B (en) | Construction of brucellosis A19 molecular marker vaccine strain and determination of virulence and immunogenicity | |
CN114807060B (en) | Coxsackie virus A6 type strain and immunogenic composition and application thereof | |
CN114107228A (en) | Construction of attenuated African swine fever virus strain with twelve genes deleted and application of attenuated African swine fever virus strain as vaccine | |
CN104560855B (en) | Lack phoP riemerella anatipestifer CH1 attenuated strains and construction method | |
CN106701650B (en) | One plant of riemerella anatipestifer gene delection low virulent strain and its construction method and application | |
Khabiri et al. | Introduction of a Newcastle disease virus challenge strain (sub-genotype VII. 1.1) isolated in Iran | |
CN106929485A (en) | Pseudorabies virus genetic engineering gB recombinates attenuated vaccine strain and application | |
Santhyia et al. | Molecular variations in Vibrio alginolyticus and V. harveyi in shrimp-farming systems upon stress | |
CN106906141B (en) | Screening method of live aeromonas hydrophila vaccine strain | |
CN108410784B (en) | Streptococcus suis delta CPS/SsnA-mSly (P353L) -SC19 engineering bacteria and application thereof in vaccines | |
CN108251382A (en) | A kind of porcine pseudorabies virus causes weak method and its causes weak Strain, vaccine composition and application | |
CN101979503B (en) | Recombinant brucella for expressing Asia type-I foot and mouth disease virus VP1 genes and method for producing vaccines thereof | |
CN104726387B (en) | A kind of actinobacillus pleuropneumoniae attenuated strain and its prevention pig pleuropneumonia product of preparation | |
CN103484397B (en) | The haemophilus parasuis engineered strain of the non-resistant labelling of a kind of hhdA gene delection and construction method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |